Short answer
Nuvalent, Inc. (NUVL) filed an 8-K current report with the SEC on April 7, 2026 reporting Item 8.01 (Other Events). FDA New Drug Application submitted for neladalkib in TKI-pretreated advanced ALK-positive NSCLC.
Nuvalent, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA New Drug Application submitted for neladalkib in TKI-pretreated advanced ALK-positive NSCLC
- Regulatory milestone advances neladalkib toward potential U.S. approval and commercialization
- Application targets patients with prior tyrosine kinase inhibitor treatment, defining initial commercial opportunity
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Nuvalent, Inc. 8-K filings
Get the next NUVL 8-K as it lands
Follow NUVL for push alerts, or ask the research agent what this filing means.